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ABSTRACT  
Introduction 
Implantable pump therapy adopting intraperitoneal route of insulin delivery has been 
available for the past three decades. The key rationale for implantable pump therapy is the 
restoration of the portal-peripheral insulin gradient of the normal physiology. Uptake in 
clinical practice is limited to specialised centres and selected patient populations.  
Areas covered 
Implantable pump therapy is discussed including technical aspects, rationale for its use, and 
glycaemic and non-glycaemic effects. Target populations, summaries of clinical studies and 
issues related to implantable pump therapy are highlighted. Limitations of implantable pump 
therapy and its future outlook in clinical practice are presented. 
Expert opinion 
Although intraperitoneal insulin delivery appears closer to the normal physiology, technical, 
pharmacological, and costs barriers prevent a wider adoption. Evidence from clinical studies 
remains scarce and inconclusive. As a consequence, the use of implantable pump therapy 
will be confined to a small population unless considerable technological progress is made 
and well-conducted studies can demonstrate glycaemic and/or non-glycaemic benefits 
justifying wider application. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Introduction 
Type 1 diabetes is a chronic autoimmune condition characterised by destruction of 
beta cells and consequential insulin deficiency[1]. Insulin replacement therapy is the 
mainstay of treatment aiming to replicate physiological levels of circulating insulin 
attained by the healthy pancreas. Modern clinical management is by multiple daily insulin 
injections to cover basal insulin and prandial requirements, and insulin pump therapy 
which delivers insulin by applying pre-programmed basal rates and insulin boluses at 
meal times  allowing greater flexibility[2].  
The first externally worn insulin pump devices were developed in 1977 and delivered 
insulin subcutaneously[3]. The rationale for implantable pump (IP) therapy was instigated 
by the need for a more physiological route of insulin delivery, whilst mitigating body wear 
issues and device burden. The first implantable pump was applied in 1979[4] with the 
expected  progress towards the implantable artificial pancreas, which unfortunately failed 
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to materialise. Early generations of IP utilised either intravenous or intraperitoneal routes, 
depending on the IP model used[5]. However, due to the greater risk of thrombosis and 
infection observed with the latter, the intraperitoneal route has prevailed[6].  
 Although from a physiological standpoint, IP insulin delivery appears to be an 
attractive alternative and closer to the normal physiology, its clinical application remains 
limited to selected groups of patients and restricted to specialised clinical centres[7-10]. 
The technical properties of the IP systems, physiological aspects related to 
intraperitoneal insulin delivery, clinical evidence, limitations and outlook are discussed in 
this review, with focus on intraperitoneal IP systems. An electronic search of Medline (via 
Pubmed) and the public register of clinical trials (www.clinicaltrials.org) was conducted. 
Keywords (implantable pump, intraperitoneal insulin delivery, type 1 diabetes, clinical 
trials) combined with relevant MeSH terms were used. A secondary search strategy was 
conducted using these keywords and terms in the abstract databases, and the 
bibliographies of retrieved papers were searched. Additional papers known to the 
authors were used.  
 
2. Technical description and overview of implantable pumps 
The first generation of commercial intraperitoneal IP systems developed in the 1980’s 
and 1990’s included the MIP 2001 pump (Minimed), the Promedos ID1/ID3 pump 
(Siemens AG), and the Model 1000 pump (Infusaid)[5, 6, 11]. The MIP 2007D pump 
(Medtronic Minimed, Northridge, CA, USA) is currently the only available commercial IP 
system. Its clinical use is limited to Europe.  
IP systems are implanted at the lower quadrants of the abdomen under general 
anaesthesia[12] (Figure 1). The MIP 2007D pump has a diameter of 8cm, thickness of 
2cm and contains up to 15ml of insulin which is delivered via a catheter placed within the 
peritoneal cavity. The tip of the catheter is directed towards the liver. Post-procedure, 
patients are required to undergo 24 hours of strict bedrest, followed by wearing a 
supportive belt for 4 to 6 weeks. They are restricted from lifting heavy weights and 
strenuous physical activity for 6 weeks post-procedure. Insulin delivery is remotely 
controlled by the user using a pager-sized hand-held device which allows for bolus 
delivery at mealtime and to correct high glucose values with pre-programmed basal 
infusion rates (Figure 2). The insulin reservoir is refilled transcutaneously through a 
central insulin refill port at a dedicated outpatient clinic at least every 3 months, 
depending on individual insulin requirements. The IP device components are 
biocompatible to avoid rejection and adverse reactions, and currently have a power 
source lasting up to 7-10 years. The IP insulin reservoir has an additional side-port to 
support technical maintenance such as rinsing in case of catheter occlusion.  
Apart from the technical equipment and the need for specialist input and expertise, 
intraperitoneal insulin delivery imposes specific challenges on insulin formulation. 
Increased insulin stability is required compared to subcutaneous delivery due to factors 
which aggravate the risk of insulin precipitation such as higher ambient temperature, fluid 
turbulence related to the pumping mechanism and interactions with surface 
materials[13]. A highly concentrated formulation such as U-400 is normally used to 
prolong the interval between reservoir refills. 
 Widespread pump failures in 1994[14] were attributed to precipitation of a new insulin 
formulation in the pump reservoir, highlighting issues associated with insulin stability 
during intraperitoneal delivery. A follow-up semisynthetic neutral human insulin 
preparation Hoe 21 GH (Hoechst AG, Frankfurt, West Germany) was marketed in 1998 
as Insuplant (U-400). Insuplant contains a surface-active agent (polyethylene-
polypropylene glycol) which increases its stability[15]. The move to human recombinant 
insulin synthesis has led to the development of Insuman implantable insulin (U-400; 
Sanofi-Aventis, Frankfurt Germany) in 2012, and is currently the only available insulin for 
intraperitoneal insulin delivery. Rapid acting insulin analogues are not approved for 
intraperitoneal delivery. Insuman has been shown to be non-inferior to Insuplant in terms 
of HbA1c change from baseline and the accuracy of pump delivery[16]. The pivotal study 
also showed comparable insulin doses, rates of hypoglycaemia, and technical and 
metabolic adverse events between the two insulin preparations.  
 
3. Physiological justification of intraperitoneal insulin delivery  
Endogenous insulin secretion into the portal vein results in preferential exposure of 
the liver to insulin. Studies in humans and animal models have shown that insulin 
concentrations during steady state conditions are typically two- to fourfold higher in the 
portal vein than in the periphery following rapidly pulsating insulin delivery by the 
pancreas[17-19]. A positive portal to systemic insulin gradient assists in balancing 
hepatic glucose output and peripheral glucose disposal, thereby maintaining glucose 
homeostasis in both postprandial and postabsorptive periods[20]. Conventional 
subcutaneous insulin delivery attains glycaemic control in a less favourable physiological 
manner as the positive portal to systemic insulin gradient and the pulsatile insulin 
concentration in the portal system are lost given that insulin is diffused from a 
subcutaneous depot into the central circulation. Subcutaneous insulin administration 
needed to regulate hepatic glucose production results in higher-than-physiological insulin 
concentrations at the peripheral tissues (Figure 3).  
It has been argued that the resulting peripheral overinsulinization by subcutaneous 
insulin shifts the primary site of insulin action away from the liver towards the skeletal 
muscle, predisposing to hypoglycaemia. This is compounded by the skeletal muscle 
being a larger glucose sink than the liver due to the higher percentage of total mass 
which takes up glucose regardless of glycaemic levels. In contrast, hepatic glucose 
uptake is diminished under hypoglycaemic conditions, and is moderate under 
euglycaemic conditions[21]. Thus, relative hepatic hypoinsulinaema shifts glucose 
storage away from the liver towards the muscle contributing to excess hepatic glucose 
output[22].  
Subcutaneously administered regular insulin has a slower absorption rate compared 
to intraperitoneally delivered insulin[23].  However, this advantage may be lost with rapid 
insulin analogues which are approved for subcutaneous but not for intraperitoneal 
delivery, and also due to the high insulin concentration needed for intraperitoneal 
delivery, which is known to slow down the rate of insulin absorption. A number of factors 
such as the anatomical region, the depth of the insulin injection, the degree of fibrosis, 
and the local blood flow may contribute up to 35% variability in insulin absorption of rapid 
insulin analogues from the subcutaneous tissue. It is hypothesised that this variability 
could be ameliorated by the application of intraperitoneal insulin delivery although exact 
data for the latter are yet to be quantified[24]. 
Intraperitoneal insulin delivery has been suggested to restore partially the positive 
portal to systemic insulin gradient. Intraperitoneal insulin delivery infuses insulin directly 
into the intraperitoneal space. Insulin is then absorbed via the capillaries of the visceral 
peritoneum into the portal vein[25]. The integrated rise in plasma insulin is notably 
reduced by 50% with intraperitoneal insulin delivery, suggesting a considerable first pass 
effect with significantly lower peripheral insulin levels.   
The differential effects of portal and peripheral insulin delivery on glucose turnover 
have been investigated in several studies using stable isotopes. A recent proof of 
concept study demonstrated that in the setting of induced hypoglycaemia, by either 
dose-matched portal or peripheral insulin administration, glucose utilisation and the 
consequent fall in glucose levels were significantly more pronounced by the 
subcutaneous as opposed to portal route[26]. Although the effect of portal compared to 
subcutaneous insulin delivery on glucose disposal is known, the evidence of its effect on 
hepatic glucose output is inconsistent. Whereas some studies have shown decreased 
hepatic glucose output, others have not been able to reproduce these findings[27-29].
  
 
4. Endocrine effects of intraperitoneal insulin delivery– beyond glycaemia 
Due to the higher portal and lower systemic insulin levels, several non-glycaemic and 
endocrine effects have been associated with intraperitoneal insulin delivery. 
Intraperitoneal insulin delivery has been suggested to augment glucagon response as 
reported in one study where subjects with type 1 diabetes receiving subcutaneous and 
intraperitoneal insulin pump therapy underwent identical hyperinsulinaemic 
challenges[30]. Whilst a significant increase in the plasma glucagon concentration was 
observed during the latter, no such increase was seen during the former.  
Portal insulin is critical for hepatic glycogen storage[31]. This may be an important 
mitigation against hypoglycaemia. To date, no clinical studies have investigated liver 
glycogen metabolism in subjects receiving portal insulin delivery. As peripheral over-
insulinisation has been linked to an increase in body weight and fat mass, emulating the 
physiological portal to systemic insulin gradient through portal insulin delivery may be 
beneficial for weight management[32]. 
Portal insulin delivery has been shown to normalize altered IGF-1 axis in individuals 
with type 1 diabetes with an observed increase in IGF-1 bioactivity, IGF-I and IGF-II 
levels as well as a decrease in IGF1BP-1 levels following intraperitoneal insulin 
delivery[33]. The clinical significance of these effects remains unclear but may include 
reversal of peripheral insulin resistance as well as anabolic effects on IGF-1 sensitive 
tissues such as the skeletal muscle and bone.  
Portal insulin delivery has also been shown to influence sex hormone binding 
globulin (SHBG) levels. Decreased levels of SHBG in males with type 1 diabetes during 
portal insulin delivery have been reported[34]. However, the clinical relevance of these 
findings remains unclear and requires further investigations. The lower peripheral  insulin 
concentrations associated with intraperitoneal insulin delivery are known to affect the 
lipid profile[35-37]. Lower VLDL triglycerides and VLDL apolipoprotein B and higher HDL 
and HDL3 cholesterol during portal insulin delivery have been reported in one study 
suggesting a lower atherogenic potential[37]. Vitamin D activation with resulting higher 
levels of plasma 25-hydroxyl vitamin D[38] has been linked to portal insulin delivery 
further highlighting its potential endocrine and metabolic effects.  
 It is important to note that the aforementioned studies which reported on endocrine 
and metabolic findings of intraperitoneal insulin delivery were relatively small and 
underpowered. Any clinical significance of the suggested effects is therefore speculative 
and requires further investigations. 
 
5. Target population for “last-resort” treatment 
Experts in the field including the EVAluation dans le Diabète des Implants ACtifs 
(EVADIAC) group[39] and others have reviewed available evidence and published 
guidelines based on clinical experience and consensus for patient selection for 
intraperitoneal insulin delivery[7]: 
• The failure to reach adequate glycaemic control or occurrence of frequent 
hypoglycaemic episodes including recurrent severe hypoglycaemia (often combined 
with hypoglycaemia unawareness). Patients who experience fear of hypoglycaemia 
and consequently have maladaptive behaviours leading to a chronic hyperglycaemic 
state may also benefit from implantable pump therapy;  
• Impaired subcutaneous insulin absorption (e.g. due to skin reactions, allergies, or 
extensive lipohypertrophy)[40]; 
• Frequent hospital admissions as a result of suboptimal metabolic control due to poor 
acceptance and management of insulin therapy[41].  
 
The contra-indications listed below should also be considered by healthcare 
providers when prescribing intraperitoneal insulin delivery: 
• Health conditions or work environments incompatible with portal insulin delivery (e.g. 
immunodeficiency syndromes, exposure to high-intensity magnetic field or very 
low/high atmospheric pressure); 
• Children or adolescents; 
• Pregnancy (due to lack of clinical data and regulatory approval of the insulin 
formulation). 
 
In cases where the expected benefits are unclear, the indication of IP therapy should 
be based on a comprehensive assessment of the individual’s clinical and psychological 
status by experienced staff and a careful risk/benefit assessment.  
 
6. Evidences from clinical studies 
6.1 Pilot and early feasibility studies 
An early feasibility study using the stabilised Hoe 21 GH insulin in the Promedos ID 1 
implantable pump (Siemens AG, Erlangen, West Germany) which delivered insulin via 
the intravenous and intraperitoneal route was assessed over a one-year period in twenty 
adults with type 1 diabetes[5]. The authors combined findings from intraperitoneal and 
intravenous routes as no significant differences in glucose levels and HbA1c between 
the two approaches were observed. The authors reported that 63% of self-monitoring 
blood glucose measurements were within the range 3.3 to 8.9mmol/l, with three glucose 
measurements per patient-month below 2.8mmol/l and 0.22 hypoglycaemia episodes per 
patient year requiring medical attention. Due to the inherent issues related to intravenous 
access, thrombosis and the risk of blood-borne infections[42], intravenous insulin 
delivery has not been deemed feasible for ambulatory implantable pump use. 
Intraperitoneal insulin delivery has since become the preferred route for the IP use, and 
early clinical studies have been performed to evaluate its feasibility in type 1 diabetes 
(Table 1). 
A pilot study in 18 participants receiving IP over 28-patient years showed that 
glycaemic control was sustained (mean HbA1c 8%) and glucose variability reduced 
without episodes of severe hypoglycaemia or diabetic ketoacidosis[11]. Four users 
experienced catheter-occlusions and the authors reported that approximately 80 percent 
of implantable catheters were useable for up to 1.5 years.  
A large (N=224) non-randomised multicentre prospective study reported on technical 
issues and related outcomes of the IP use[39]. The authors showed that over the 
1.5 year follow-up period, catheter obstructions were still relatively common (47 events) 
with nine pump failures requiring replacement. However, glycaemic control as measured 
by HbA1c and mean glucose were significantly improved compared to baseline (p<0.001 
for both). Long-term feasibility studies by the same group showed that technical 
improvements reduced the frequency of insulin under-delivery caused by insulin 
aggregation and increased accuracy of pump delivery[43].  
 
6.2 Randomised controlled trials 
Although IP therapy has been available in clinical practice for several decades, data 
from randomised controlled trials remain limited. Results related to glycaemic control and 
hypoglycaemic outcomes have been mixed due to the heterogeneous population of the 
comparator group in these studies (i.e. subcutaneous insulin pump and multiple daily 
injection users, various insulin preparations used such as human insulin and rapid-acting 
analogues by the comparator group) and glucose measures used (intermittent capillary 
glucose and continuous glucose monitoring), making interpretation of the results 
challenging. The small number of participants limited statistical power especially for 
hypoglycaemia-related outcomes. The small number of participant may be partly 
attributable to the highly selected patient population deemed appropriate for this therapy, 
and the low number of specialist centres with clinical expertise and skills to manage IP 
devices which required input both from the diabetes and surgical teams.  
An early randomised controlled parallel design study compared IP delivering 
intraperitoneal insulin against optimised subcutaneous insulin therapy administered by 
either multiple daily injections or subcutaneous insulin pump[44]. There were no 
significant differences in HbA1c levels or severe hypoglycaemia events between the two 
groups, with both groups achieving a comparable HbA1c reduction relative to baseline. 
Longitudinal within group comparisons showed that glycaemic variability as measured by 
the standard deviation of capillary glucose was notably reduced by IP [4.3±0.4 vs. 
3.2±0.5mmol/l in the IP group (p<0.005) and 3.7±0.3 vs. 4.0±0.4mmol/l in the 
subcutaneous insulin group (p>0.05)]. Conversely, a randomised controlled cross-over 
design study comparing intraperitoneal insulin infusion via IP to subcutaneous insulin via 
multiple daily injections showed that IP users had significantly lower HbA1c (7.2±0.2 vs. 
8.5±0.7%, p=0.02), glycaemic variability as measured by the standard deviation of 
capillary glucose (3.4±0.2 vs. 4.6±0.2mmol/l, p<0.01) and hypoglycaemic events 
(5.7±2.0 vs. 10.0±3.1 events/month, p=0.02)[45].  
A single centre randomised cross-over design study compared IP delivering 
intraperitoneal insulin in 24 suboptimally controlled adults with type 1 diabetes (mean 
baseline HbA1c  8.6%) against a heterogeneous group of subcutaneous insulin therapy 
users (insulin pump and multiple daily injection)[8]. There were no reported differences 
between the groups in the study’s primary endpoint (the number of hypoglycaemic 
events, p=0.13), although IP use reduced HbA1c levels by 0.76% (p=0.03) without 
significantly increasing total daily insulin (p=0.57). Quality of life was notably improved in 
IP compared to subcutaneous insulin therapy users. 
 
6.3 Long-term follow-up clinical studies 
Limitations of randomised controlled trials involving IP include the relatively short 
duration of studies ranging from 9 to 16 months, and a small number of participants. 
Long-term observational studies have provided insights into the safety, efficacy, and 
tolerability of IP therapy over prolonged use as well as its impact on quality of life in 
larger patient populations[10, 46]. 
In one of the longest follow-up study to date, no significant difference in HbA1c 
was found among 19 of 23 patients who received IP for 6 years, compared to their pre-IP 
period, following optimisation of subcutaneous insulin therapy [mean estimated change of 
HbA1c −0.1mmol/mol, 95%CI (-10.5, 10.3); p=1.0][9]. Although a significant reduction in 
the number of capillary glucose values below 3.5mmol/l was observed, continuous 
glucose monitoring sensor measurements showed significantly greater time spent in the 
hyperglycaemic range at the 6-year follow-up [mean change 19.8% (95% CI 3.0, 36.6), 
p=0.013].  
Treatment satisfaction, as measured by the Diabetes Treatment Satisfaction 
Questionnaire (DTSQ), was reportedly higher at follow-up with IP than subcutaneous 
insulin therapy, albeit with notably higher perceived hyperglycaemic score of the DTSQ. 
Health-related quality of life measures remained high and stable throughout the study.  
There were three reported technical pump failures over a mean study duration of 5 years, 
and 4 users required either laparoscopic procedures or operations for catheter-related 
complications. There was no reported mortality over the whole study period. 
 7. Challenges and issues related to implantable pump therapy  
In spite of the reported benefits on treatment satisfaction, studies evaluating IP 
therapy have reported issues and technical limitations such as pump malfunctions which 
are generally more difficult to resolve compared to subcutaneous insulin pump therapy. 
Modern IP devices present fewer of these issues[43, 47].  The most common are local 
complications at the abdominal implantation site and insulin under-delivery. Reported 
occurrences of local complications, which included pump site infections, fluid collections 
as well as skin atrophy or erosions, have decreased from eight to less than two per 100 
patient-years, from the early 1990s to present[43, 48-50]. Most infections are related to 
bacterial seeding from the skin during surgical and maintenance-related procedures, e.g. 
repeated transcutaneous punctures of the pump pocket for insulin refill.  Suggested 
approaches to mitigate against local infections include peri-procedural antibiotic 
coverage and antiseptic cleaning of the surrounding skin.  
Insulin under-delivery may develop steadily over time[51] and is reflected by an 
increase in insulin requirements needed to maintain glucose control. This may be related 
to occlusions in the pumping system caused by either biological materials such as fibrin 
clots or encapsulation, or insulin aggregation.  As the latter has been thought to be a 
common cause of insulin under-delivery, a pragmatic solution includes regular rinsing of 
the tubing system with sodium hydroxide[52]. 
Several studies in the 1990s reported an increase of anti-insulin antibody levels 
during IP use[53-55], which occurred as early as the third month following implantation. 
The increased immunogenicity was attributed to factors such as the insulin formulation 
(HOE 21 PH insulin), the route of delivery - the peritoneum is a macrophage-rich area 
which may bolster lymphocytes activation and antibody production - as well as insulin 
aggregates formed in the pumping system[56]. Of note, this immune reaction is highly 
variable and the only identifiable predictive factor appears to be the anti-insulin antibody 
level before implantation, however, its clinical significance is unclear.  
 
8. DiaPort – intraperitoneal insulin delivery with externally worn pump 
Due to the invasive nature and associated risks of IP, DiaPort (Roche Diagnostics, 
Mannheim, Germany) has been developed, which is an alternative approach for 
intraperitoneal insulin delivery[57]. DiaPort utilises a percutaneous insulin port connected 
to an external pump device. It consists of a small titanium-encased body which is 
biocompatible and is implanted into the subcutaneous tissue. DiaPort has made 
intraperitoneal insulin delivery more feasible in clinical practice due to its less invasive 
application procedure compared to IP[32]. In a multi-centre cross-over design study, 
sixty participants with type 1 diabetes were randomised to intraperitoneal insulin infusion 
using DiaPort with regular insulin (Insuman U-100) or to subcutaneous insulin pump 
therapy with lispro for 12 months[32]. The primary endpoint based on intention to treat 
analysis showed that the incidence of hypoglycaemia was comparable between the 
treatments (p=0.91) whereas the number of severe hypoglycaemia events was halved 
during the DiaPort use (34.8 vs. 86.1 events / 100 patient years, p=0.013). The number 
of dropouts during the study was relatively high (24/30 and 12/30 participants in the 
DiaPort and subcutaneous insulin pump group, respectively), which the authors 
attributed to participants’ fear of potential complications of intraperitoneal delivery, 
leading to reluctance to use it.   
The second-generation DiaPort system was introduced in 2011. Information obtained 
from the manufacturer suggests that compared to its predecessor, improvements have 
been made to the implantation method, design and materials. These modifications were 
implemented to simplify the implantation procedure and to reduce further the risk of 
infection and catheter obstruction. There are no randomised clinical trials of the second 
generation DiaPort system currently available. Non-randomised single-arm studies with a 
relatively small number of participants have been performed (i.e. ClinicalTrials.gov 
NCT01483352) and results are yet to be published.  
 
9. Implantable pump and artificial pancreas 
Closed-loop systems, also known as the Artificial Pancreas, are considered a bridge 
to a biological cure. A closed-loop system consists of an insulin pump, a continuous 
glucose monitoring sensor and a control algorithm[2].  Insulin delivery is directed by the 
control algorithm in a glucose-responsive fashion. Closed-loop systems have been 
tested in up to 6-month home studies using the subcutaneous route for both glucose 
sensing and insulin delivery[58-61]. The first closed-loop insulin delivery system adopting 
subcutaneous insulin delivery route has been approved by the US Food and Drug 
Administration based on a recent pivotal study[62]. Limitations remain with regards to 
delays in insulin absorption and action inherently linked to the subcutaneous route of 
insulin delivery. If intraperitoneal insulin infusion from IP therapy could provide faster and 
less variable insulin action, integrating IP into closed-loop system would be a promising 
approach. However, the lack of rapid acting insulin analogues for intraperitoneal delivery 
remains an obstacle. The feasibility of closed-loop IP insulin delivery system adopting 
intravenous[63] and subcutaneous glucose sensors has been demonstrated. A non-
randomised controlled trial of closed-loop intraperitoneal insulin delivery via DiaPort was 
recently completed but results are yet to be published (ClinicalTrials.gov NCT01555788).  
 
10. Expert – Outlook and future of implantable pump therapy 
The development and interest of IP therapy stemmed from the conjecture that 
intraperitoneal insulin delivery may restore the physiological portal-systemic insulin 
gradient thereby circumnavigating the unfavourable effects of subcutaneous insulin 
which impedes satisfactory postprandial control and may lead to delayed postprandial 
hypoglycaemia and increased glycaemic variability. Portal insulin delivery, with 
potentially faster time-to-peak insulin action and return-to-baseline (“on-and-off” of insulin 
action) and better reproducibility of insulin absorption could improve the efficacy and 
safety of present management approaches. This may also enhance closed-loop 
performance, which is currently hampered by delayed subcutaneous insulin kinetics[59, 
60]. Studies have provided insights into both glycaemic and non-glycaemic outcomes of 
intraperitoneal/portal insulin delivery, showing potential amelioration of metabolic and 
endocrine dysregulation in type 1 diabetes, although data supporting the clinical 
significance of these observations are lacking. In addition, most evidence justifying the 
pharmacokinetic benefits of IP insulin delivery is based on outdated studies in the pre-
insulin analogue era[23]. Research in the field is limited by the lack of innovation, the 
lack of rapid acting insulin analogues for intraperitoneal delivery, and the small niche 
target population which may deter commercial interest. 
Findings from clinical studies have overall been inconclusive and challenging to 
interpret due to the inherent limitations of study designs and populations, various insulin 
preparations and regimes used. The limited numbers of prospective randomised 
controlled trials have shown modest reductions in HbA1c and glycaemic variability. Most 
recent studies of IP, or intraperitoneal insulin delivery via DiaPort, have yet to be 
published. The scientific progress inertia in this field is in contrast with the rapid 
advances and innovations surrounding  subcutaneous insulin pump technology and 
associated rapid acting insulin analogues[62, 64]. Hypoglycaemia outcomes have been 
inconsistent, likely due to the small sample size and limited continuous glucose 
monitoring available in early studies. Regulatory approval of IP is currently restricted to 
Europe, and used in clinical practice in Belgium, France, Sweden and the Netherlands. 
Several groups with extensive experience of IP use, such as the EVADIAC group, have 
formulated clinical guidelines and patient selection criteria. 
Cost implications have limited the wider clinical use and availability of IP in many 
countries. The estimated direct pump and procedure-related (i.e. filling and rinsing 
procedures) costs in 2010 for IP therapy were approximately 31,000 Euros in the first 
year, and 7,500 Euros for the following 6 years[65]. Other incurred costs such as the 
specific insulin formulation used and the need for specialist teams which include 
technical and surgical input. This results in IP therapy being costlier than conventional 
subcutaneous insulin therapy, either by multiple daily injections or insulin pumps. The 
annual costs of IP is approximately 6,000 Euros higher than subcutaneous insulin pump 
therapy[10].   
Based on the aforementioned limitations such as the risk of complications, the need 
for more clinical evidence, higher costs, and the rapid development of subcutaneous 
insulin-based therapies (i.e. ultra-fasting acting analogues) and non-insulin adjunctive 
therapies, the incremental benefits of IP in the wider population of people with type 1 
diabetes remain debatable. Well-conducted studies supporting the clinical benefits from 
glycaemic and non-glycaemic, endocrine and metabolic effects of IP are needed to 
provide stronger justification for its wider use in clinical practice but it is unclear whether 
there is sufficient appetite and justification to do so.  
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Table 1. Summary of studies comparing implantable pump therapy with subcutaneous insulin therapy.  
 Study design Intervention Comparator N Study duration Main findings Reference 
Ea
rly
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ea
si
bi
lit
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st
ud
ie
s 
Single-arm 
observational 
study 
IP - 
 
20 1-year 62·9% capillary glucose measurements between 3·3-8·9mmol/l. 3.3 
glucose measurements per patient-month in the hypoglycaemic range 
(<2·8mmol/l) and 2·6 episodes of hypoglycaemia per patient-month, 0·22 
severe hypoglycaemia episodes per patient-year. Median HbA1c at 
baseline 7.6%, and 7·0% at the end of the trial (p <0·05). 
 
[5] 
Single-arm 
observational 
study 
IP - 18 4-25 months 
(mean 18 
months) 
Mean plasma glucose level 7.3mmol/l; mean HbA1c 8% and significantly 
reduced glycaemic fluctuations during IP therapy. Total mean daily insulin 
dose did not change compared to baseline. No surgical complications, or 
severe hypoglycaemia or diabetic ketoacidosis episodes. Four patients 
had catheter blockages, one pump had manufacturing defect.  
[11] 
Single-arm 
observational 
study  
Post-IP Pre-IP 224 1 – 40 
months (353 
patient-years) 
Mean HbA1c decreased from 7.4 to 6.8% (p<0.001). Mean glucose 
decreased from 8.7 to 7.8mmol/l (p<0.001).   
[39] 
R
an
do
m
is
ed
 c
on
tr
ol
le
d 
st
ud
ie
s 
Randomised, 
prospective, 
cross-over 
design. 
IP MDI, CSII 21 6 months No significant differences in HbA1c or severe hypoglycaemia events 
between groups.  
[44] 
Randomised, 
prospective, 
cross-over 
design.  
IP MDI 10 6 months IP significantly decreased HbA1c (7.2 ± 0.2 vs. 8.5 ± 0.7%, p =0.02), 
reduced glycaemic variability (SD of capillary glucose 3.4 ± 0.2 vs. 4.6 ± 
0.2mmol/l, p<0.01).  
[45] 
Randomised, 
prospective, 
cross-over 
design 
IP MDI, CSII 24 16 months No significant difference in incidence of hypoglycaemia. IP significantly 
decreased HbA1c by -0.76% (95% CI -1.41 to -0.11, p=0.03). and 
increased time spent euglycaemic by 11% (p=0.003) with no difference in 
total daily insulin use. 
[8] 
Lo
ng
-te
rm
  
fo
llo
w
-u
p 
st
ud
ie
s 
Prospective, 
observational, 
case control 
design 
IP MDI, CSII 183 26 weeks HbA1c did not significantly change within IP group, and significantly 
decreased within control group by -0.09% (95% CI -0.17 to -0.01). 
Difference between treatment groups was -0.27% (95% CI -0.46 to -0.09). 
Number of blood glucose <4.0mmol/l decreased by 1.2(95% CI -1.7 to -
0.7) within control group, and was non-significant in the IP group. 
[10] 
Non-
randomised, 
retrospective 
design 
IP - 181 5 years HbA1c decreased from 7.9±1.2 to 7.6±1.2% (p<0.01) after the first year of 
implantation, and remained significant lower than baseline (p<0.05) 
throughout subsequent years.  
[46] 
IP = intraperitoneal pump, MDI= multiple daily injections, CSII= continuous subcutaneous insulin infusion 
Figure 1. Anatomical location and components of implanted pump device (Copyright © 2009 
American Diabetes Association. From: Diabetes Care 2009 Aug; 32(8): 1372-1377. Reprinted 
with permission from The American Diabetes Association). 
  
  
 
 
 
 
 
 
 
Figure 2. The MIP 2007D implantable pump with hand-held device (reprinted with permission 
by Medtronic).  
  
  
Figure 3. Schematic outline of the pharmacological and physiological properties of 
intraperitoneal and subcutaneous insulin delivery. 
